阿非卡坦用于梗阻性肥厚型心肌病 - Suppr

Suppr

超能文献

Aficamten for Obstructive Hypertrophic Cardiomyopathy.

作者信息

Li Peng

机构信息

Beijing Hospital, Beijing, China

出版信息

N Engl J Med. 2024 Aug 15;391(7):664-665. doi: 10.1056/NEJMc2408094.

DOI:10.1056/NEJMc2408094

PMID:39141863

Abstract

摘要

相似文献

Aficamten for Obstructive Hypertrophic Cardiomyopathy.阿非卡坦用于梗阻性肥厚型心肌病

N Engl J Med. 2024 Aug 15;391(7):664-665. doi: 10.1056/NEJMc2408094.

Aficamten for Obstructive Hypertrophic Cardiomyopathy. Reply.阿非卡坦用于梗阻性肥厚型心肌病。回复。

N Engl J Med. 2024 Aug 15;391(7):665-666. doi: 10.1056/NEJMc2408094.

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics.阿菲卡坦与美托洛尔治疗梗阻性肥厚型心肌病：MAPLE-HCM研究原理、研究设计及基线特征

JACC Heart Fail. 2025 Feb;13(2):346-357. doi: 10.1016/j.jchf.2024.11.011.

Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM.接受阿非卡肽治疗的梗阻性肥厚型心肌病患者的标准药物治疗停药：FOREST-HCM 研究。

J Am Coll Cardiol. 2024 Nov 5;84(19):1839-1849. doi: 10.1016/j.jacc.2024.09.002.

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.肥厚型梗阻性心肌病的治疗药物：Aficamten

N Engl J Med. 2024 May 30;390(20):1849-1861. doi: 10.1056/NEJMoa2401424. Epub 2024 May 13.

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.阿非卡肽对梗阻性肥厚型心肌病患者疾病和症状负担的影响：SEQUOIA-HCM 研究结果。

J Am Coll Cardiol. 2024 Nov 5;84(19):1821-1831. doi: 10.1016/j.jacc.2024.09.003. Epub 2024 Sep 30.

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.马伐卡坦和阿非卡坦在肥厚型心肌病患者中的安全性和有效性

J Am Heart Assoc. 2025 Mar 18;14(6):e038758. doi: 10.1161/JAHA.124.038758. Epub 2025 Mar 7.

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.肥厚型梗阻性心肌病患者中阿非卡肽的剂量和安全性特征：SEQUOIA-HCM 研究结果。

J Am Heart Assoc. 2024 Aug 6;13(15):e035993. doi: 10.1161/JAHA.124.035993. Epub 2024 Jul 26.

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.阿菲卡明治疗梗阻性肥厚型心肌病患者的2期研究。

J Am Coll Cardiol. 2023 Jan 3;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020.

Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.接受丙吡胺治疗的药物难治性重度梗阻性肥厚型心肌病患者使用阿菲卡坦：红木-HCM队列3

J Card Fail. 2023 Nov;29(11):1576-1582. doi: 10.1016/j.cardfail.2023.07.003. Epub 2023 Jul 18.

引用本文的文献

Osteosarcopenia in older adults undergoing transcatheter aortic valve replacement: A narrative review of mortality and frailty implications.接受经导管主动脉瓣置换术的老年人中的骨质肌肉减少症：关于死亡率和衰弱影响的叙述性综述

World J Cardiol. 2025 May 26;17(5):107320. doi: 10.4330/wjc.v17.i5.107320.

From surgery to recovery: Measuring success through quality of life and functional improvements after cardiac surgery.从手术到康复：通过心脏手术后的生活质量和功能改善来衡量成功

World J Cardiol. 2025 Feb 26;17(2):100213. doi: 10.4330/wjc.v17.i2.100213.

Comparative breakthrough: Umbilical cord mesenchymal stem cells bone marrow mesenchymal stem cells in heart failure treatment.比较性突破：脐带间充质干细胞与骨髓间充质干细胞在心力衰竭治疗中的比较

World J Cardiol. 2024 Dec 26;16(12):776-780. doi: 10.4330/wjc.v16.i12.776.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验